Aprepitant: all 129 studies that test it

Page 1 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Aprepitant for the Treatment of CLIFAHDDRecruitingNCT07845825Early Phase 1
• Aprepitant to Improve Same Day Discharge for TKANot yet recruitingNCT07639723Phase 4
• Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryNot yet recruitingNCT07371728Phase 4
• Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer PatientsNot yet recruitingNCT06931119Phase 1
• Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingNot yet recruitingNCT06543966Phase 3
• Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis SurgeryRecruitingNCT06357234Phase 2
• Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingNCT05841849Phase 4
• Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataCompletedNCT04606264Phase 3Results posted
• Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve GastrectomyCompletedNCT03435003Phase 4Results posted
• Low Dose Aprepitant for Patients Receiving CarboplatinTerminatedNCT03237611Phase 2Results posted
• Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose MelphalanCompletedNCT02939287Phase 3Results posted
• Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) ProphylaxisCompletedNCT02625181Not applicableResults posted
• Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and DependenceCompletedNCT02210195Phase 2Results posted
• Effect of Chronic ACE and DPP4 Inhibition on Blood PressureCompletedNCT02130687Not applicableResults posted
• Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving ChemotherapyCompletedNCT02097823Phase 2Results posted
• Topical Aprepitant in Prurigo PatientsCompletedNCT01963793Phase 2Results posted
• Differentiating the Effects of Substance P and Beta-endorphinCompletedNCT01854177Not applicableResults posted
• A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)CompletedNCT01732458Phase 2Results posted
• A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)CompletedNCT01636947Phase 4Results posted
• Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary SyndromeTerminatedNCT01625455Phase 4Results posted
• Treatment for Cannabis Withdrawal and DependenceCompletedNCT01611948Phase 2Results posted
• The Role of Substance P on Perception of Breathlessness During Resistive Load BreathingCompletedNCT01580423Not applicableResults posted
• Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic CancerCompletedNCT01534637Phase 2Results posted
• Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and VomitingCompletedNCT01474915Phase 4Results posted
• Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving TemozolomideCompletedNCT01450826Phase 2Results posted
• Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and VomitingCompletedNCT01432015Phase 4Results posted
• A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)CompletedNCT01362530Phase 3Results posted
• Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyCompletedNCT01334086Phase 2Results posted
• Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.CompletedNCT01298193Phase 4Results posted
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot StudyTerminatedNCT01183481Phase 2Results posted
• Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin TrialCompletedNCT01149369Phase 2Results posted
• Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)CompletedNCT01111851Phase 1Results posted
• Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/CarboplatinCompletedNCT01012336Phase 2Results posted
• Aprepitant Effects on Oxycodone ResponseCompletedNCT00999544Not applicableResults posted
• A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)CompletedNCT00990821Phase 1Results posted
• Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)CompletedNCT00952341Phase 3Results posted
• The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSDCompletedNCT00896038Phase 2Results posted
• Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective HysterectomyTerminatedNCT00888329Phase 4Results posted
• A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)CompletedNCT00819039Phase 1Results posted
• A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)TerminatedNCT00818259Phase 1Results posted
• A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) PancreatitisCompletedNCT00736073Not applicableResults posted
• Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having CraniotomyCompletedNCT00734929Phase 4Results posted
• Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and VomitingCompletedNCT00717054Not applicableResults posted
• Emend for Multiple-day Emetogenic ChemotherapyCompletedNCT00711555Phase 2Results posted
• Aprepitant for PONV Prophylaxis in Outpatient Plastic SurgeryCompletedNCT00659945Phase 4Results posted
• Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma PatientsCompletedNCT00651755Not applicableResults posted
• Multi-day Doses in Prevention of Nausea and EmesisCompletedNCT00600353Phase 2Results posted
• Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell TumorsCompletedNCT00572572Phase 3Results posted
• Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOXCompletedNCT00381862Phase 2Results posted
• Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)CompletedNCT00337727Phase 3Results posted
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantCompletedNCT00293384Not applicableResults posted
• Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell TransplantCompletedNCT00248547Not applicableResults posted
• Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompletedNCT07248280Phase 3
• Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingCompletedNCT06932107Phase 3
• Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid CancerCompletedNCT06697782Phase 4
• Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary DysmenorrheaCompletedNCT06317064Phase 3
• Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedNCT06007586Phase 3
• The Effect of Aprepitant Reducing Postoperative Nausea and VomitingStatus unknownNCT05772676Phase 4
• Postoperative Nausea and Vomiting in Laparoscopic Abdominal SurgeryStatus unknownNCT05632224Phase 4
• Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.TerminatedNCT05189756Phase 4
• Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner PatientsStatus unknownNCT04873284Not applicable
• Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3CompletedNCT04649229Phase 4
• Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.CompletedNCT04399148Not applicable
• Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and VomitingCompletedNCT04013386Phase 4
• Relative Bioavailability of NXP001 Compared to Emend® in Healthy VolunteersCompletedNCT03889366Phase 1
• Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative NeoplasmsCompletedNCT03808805Phase 3
• Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic ChemotherapyCompletedNCT03674294Phase 3
• Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCCCompletedNCT03572829Phase 2
• Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult VolunteersCompletedNCT03245918Phase 1
• Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer PatientsCompletedNCT03079219Phase 3
• Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric EmptyingCompletedNCT02989467Phase 1
• Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction ChemotherapyStatus unknownNCT02979548Phase 3
• Aprepitant for the Prevention of Chemotherapy-induced Nausea and VomitingStatus unknownNCT02933099Phase 3
• Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal CancerCompletedNCT02909478Phase 3
• Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus TreatmentCompletedNCT02646020Phase 2
• A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT02576327Phase 4
• Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal MalignancyTerminatedNCT02550119Not applicable
• Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and DexamethasoneCompletedNCT02532634Phase 4
• Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological SurgeriesCompletedNCT02525848Phase 2/3
• Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin ChemotherapyStatus unknownNCT02445872Phase 2
• Palonosetron Associated to Aprepitant in Prophylaxis of PONVStatus unknownNCT02431286Phase 4
• Neurokinin Receptor Antagonist Associated to Ondansetron in PONVCompletedNCT02357693Phase 4
• Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)Status unknownNCT02347878Phase 4
• Aprepitant to Mitigate Opioids' Cognitive Side EffectsStatus unknownNCT02226601Not applicable
• Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic PatientsStatus unknownNCT02205164Phase 2
• Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung CancersCompletedNCT02161991Phase 3
• Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected SubjectsCompletedNCT02154360Phase 1
• Prevention of Nausea and Vomiting in Patients After SurgeryCompletedNCT02021851Phase 4
• Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.Status unknownNCT01913990Phase 4
• The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and VomitingCompletedNCT01897337Phase 4
• Efficacy of Aprepitant (Emend®) in ChildrenCompletedNCT01661335Phase 3
• Aprepitant Effects in Intravenous Heroin DependenceCompletedNCT01527994Phase 1
• Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic HysterectomyCompletedNCT01440673Not applicable
• Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving ChemotherapyCompletedNCT01402024Phase 3
• Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI TrialCompletedNCT01344304Not applicable
• Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg DoseCompletedNCT01300988Phase 1
• Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in AdolescentsTerminatedNCT01249001Phase 2
• Comparison of Adding EMEND to PONV/PDNV Treatment RegimenWithdrawnNCT01186029Not applicable
• Treatment of Chemotherapy-induced Nausea and VomitingCompletedNCT01101529Phase 2

← Aprepitant overview